One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term ...

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

Most AI drug development is fueled by foundation models in biology—models that are trained on vast biological data sets and ...

Bay Area startup ASC Therapeutics filed for bankruptcy on Wednesday, marking the end of the line for the gene and cell ...

The team at GV manages some $10 billion that the tech giant has set aside for early-stage companies. Schenkein’s group ...

Nanobiotix (NASDAQ: NBTX) is a French biotechnology stock, and one that has soared 660% in 2025 as of Nov. 18. That's enough ...

The unexpected bankruptcy of ASC Therapeutics has sent shockwaves through the Bay Area’s biotech community, cutting short ...

The SBIO ETF has staged a remarkable comeback, outperforming despite a challenging macro backdrop and small-cap weakness.

Since there's no information about Carvykti (cilta-cel) in the 10-K, I've opened Legend's Form 20-F. According to it, ...

A federal commission is calling for significant changes to the way the U.S. government funds and assesses scientific research ...

Kane Biotech ( ($TSE:KNE) ) has provided an announcement. Kane Biotech announced its third quarter 2025 financial results, revealing a significant ...

Drugmakers are making notable deals, biotech is coming back, and much of the worry about tariffs and interest rates has faded ...